Loading
Life sciences · Journal article
Journal of Molecular Recognition · October 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Following the rise in resistance to PD‐1/PD‐L1 immune checkpoint blockade therapy in patients with cancer, the TIGIT/CD155 axis has emerged as a major focus of current research. Several competitive binding inhibitors, including antibodies and small molecules targeting TIGIT or CD155, have demonstrated efficacy in suppressing tumor growth and metastasis, either in preclinical models or clinical trials. This review summarizes the expression patterns of CD155, TIGIT, and DNAM‐1 across immune cell subsets, along with the downstream signaling pathways modulated by these interactions. Furthermore, it provides an analysis of predicted binding sites among relevant domains. The article also systematically catalogs current therapeutic strategies targeting the CD155/TIGIT axis in patients, including novel emerging modalities.